The White House launched TrumpRx, a direct‑to‑consumer drug‑pricing hub built on GoodRx technology that displays cash prices and routes consumers to purchase options. The platform opened with a select slate of discounted products but experts and early reports say the price reductions will largely benefit cash‑paying patients and have limited impact for those whose drugs are covered by insurance. Government officials and several pharma companies struck individual discount arrangements, but analysts cautioned that formularies, rebate dynamics and insurance coverage will blunt broad patient benefit. For biotech and pharma, the rollout introduces a new channel for cash pricing and company‑level deals, while leaving systemic reimbursement and payor dynamics unchanged.